tiprankstipranks
Nuwellis reports Q4 EPS ($2.24), consensus ($1.39)
PremiumThe FlyNuwellis reports Q4 EPS ($2.24), consensus ($1.39)
2M ago
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
PremiumPress Releases
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
2M ago
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
PremiumPress Releases
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
2M ago
Nuwellis Reveals Aquadex System Success in Liver Disease
PremiumCompany AnnouncementsNuwellis Reveals Aquadex System Success in Liver Disease
3M ago
New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload
PremiumPress Releases
New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload
3M ago
Nuwellis announces new case series on potential of Aquadex therapy
PremiumThe Fly
Nuwellis announces new case series on potential of Aquadex therapy
3M ago
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress ReleasesNuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5M ago
Nuwellis downgraded to Neutral from Buy at Ladenburg
PremiumThe Fly
Nuwellis downgraded to Neutral from Buy at Ladenburg
6M ago
Nuwellis, Inc. Announces Third Quarter 2023 Financial Results
PremiumPress Releases
Nuwellis, Inc. Announces Third Quarter 2023 Financial Results
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100